Description

• General description: This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
• Application: Novel tacrine-donepezil hybrids for Alzheimer′s treatment: Research has led to the development of new tacrine-donepezil hybrid compounds targeting Alzheimer′s disease, offering enhanced bioactivity and potential therapeutic benefits. These hybrids demonstrate multifunctional approaches in addressing neurodegenerative disorders by combining the acetylcholinesterase inhibitory effects of donepezil with the neuroprotective properties of tacrine (Bayraktar et al., 2024).Role of oligodendrocytes in Alzheimer′s disease: A study explores the involvement of oligodendrocytes in Alzheimer′s pathogenesis, highlighting potential mechanisms where donepezil could be implicated in modulating neurodegenerative processes. This research underscores the broader applicability of donepezil in understanding and potentially treating Alzheimer′s disease (Wang et al., 2024).Shenghui decoction′s neuroprotective effects: Investigating traditional therapies, this study assesses the neuroprotective effects of Shenghui decoction in an Alzheimer′s disease model. Donepezil′s role in this context is compared, contributing to broader insights into potential integrative treatments for neurodegenerative diseases (Lu et al., 2024).Electrochemical sensors for Alzheimer′s drug analysis: The development of electrochemical acetylcholinesterase sensors designed for the detection and study of anti-Alzheimer drugs like donepezil underscores its importance in research and therapeutic monitoring. This advancement supports the precise administration and study of donepezil in clinical settings (Ivanov et al., 2024).Modulating neurodegeneration with donepezil: A study on the combined effects of endothelin receptor agonist IRL-1620 with donepezil in an amyloid-β induced model of neurodegeneration in rats, expands our understanding of donepezil′s therapeutic potential beyond traditional applications, suggesting its utility in complex therapeutic regimes (Mahajan et al., 2024).
• Analysis Note: These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​
• Other Notes: Sales restrictions may apply.